{"id":1057616,"date":"2012-02-28T05:00:20","date_gmt":"2012-02-28T05:00:20","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/opexa-therapeutics-reports-year-end-2011-financial-results-and-provides-corporate-update\/"},"modified":"2024-08-17T19:34:31","modified_gmt":"2024-08-17T23:34:31","slug":"opexa-therapeutics-reports-year-end-2011-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/multiple-sclerosis\/opexa-therapeutics-reports-year-end-2011-financial-results-and-provides-corporate-update.php","title":{"rendered":"Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p> THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA - News), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year. 2011 highlights include: Clinical and Regulatory Granted Fast Track designation by the U.S.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/multiple-sclerosis\/opexa-therapeutics-reports-year-end-2011-financial-results-and-provides-corporate-update.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246866],"tags":[],"class_list":["post-1057616","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1057616"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1057616"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1057616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1057616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1057616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1057616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}